Hyperhidrosis treatment with bornaprine in the acute phase of spinal cord-injured patients
Study design:Original article.Objective:To test the use of bornaprine in the hyperhidrosis treatment in the acute phase of spinal cord-injured patients.Setting:Patients with acute spinal cord lesions in the Spinal Unit of Pietra Ligure, Savona, Italy.Method:In 4 years, 12 patients have been treated, for a maximum period of 75 days, with dosages ranging from 2 to 4 mg day−1.Results:All of them reported long-lasting subjective benefits, without side effects, even after the interruption of the therapy.Conclusion:The bornaprine treatment, at 2 or 4 mg day−1 dosage, has been effective and safe to contrast hyperhidrosis, in the acute phase of spinal cord-injured patients. This positive experience would require additional trials and a larger number of cases to gain a more solid support.